{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erbitux&page=13", "query": { "intervention": "Erbitux", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 322, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erbitux&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Erbitux&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-11T23:05:07.006Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00291707", "title": "Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "radiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-03", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2013-05-06", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00291707" }, { "nct_id": "NCT00252564", "title": "Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Colorectal Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2005-09", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2019-02-15", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 82, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 74 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00252564" }, { "nct_id": "NCT02270814", "title": "Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer", "Head and Neck Squamous Cell Carcinoma", "Cancer of the Head and Neck" ], "interventions": [ { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2015-02-02", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • Jackson, Mississippi • St Louis, Missouri + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fargo", "state": "North Dakota" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02270814" }, { "nct_id": "NCT00124618", "title": "Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2006-01", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 175, "location_summary": "Scottsdale, Arizona • Hollywood, Florida • Jacksonville, Florida + 107 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Aurora", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124618" }, { "nct_id": "NCT00661492", "title": "Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Androgen-independent Prostate Cancer" ], "interventions": [ { "name": "cetuximab", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "US Oncology Research", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 115, "start_date": "2008-05", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2016-12-09", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 55, "location_summary": "Phoenix, Arizona • Sedona, Arizona • Denver, Colorado + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Melbourne", "state": "Florida" }, { "city": "New Port Richey", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00661492" }, { "nct_id": "NCT01015664", "title": "Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Tennessee Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-17", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01015664" }, { "nct_id": "NCT00498992", "title": "Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Dermatologic Complications", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "collagen/aloe vera/vitamin E/lidocaine topical hydrogel", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Ingalls Memorial Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2006-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-20", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 1, "location_summary": "Harvey, Illinois", "locations": [ { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00498992" }, { "nct_id": "NCT00044863", "title": "Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms", "Metastases, Neoplasm" ], "interventions": [ { "name": "Erbitux (Cetuximab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2002-08", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2011-02-23", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 1, "location_summary": "Saint Charles, Missouri", "locations": [ { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00044863" }, { "nct_id": "NCT02741570", "title": "Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Cetuximab/Erbitux", "type": "DRUG" }, { "name": "Cisplatin/Platinol", "type": "DRUG" }, { "name": "Carboplatin/Paraplatin", "type": "DRUG" }, { "name": "Fluorouracil/Adrucil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 947, "start_date": "2016-10-05", "completion_date": "2022-09-22", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 22, "location_summary": "Tucson, Arizona • Duarte, California • Stanford, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02741570" }, { "nct_id": "NCT05203172", "title": "The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Binimetinib", "type": "DRUG" }, { "name": "Encorafenib", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2022-07-05", "completion_date": "2032-06-30", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-11T23:05:07.006Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Atlanta, Georgia • Boston, Massachusetts + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05203172" } ] }